Blood and lymphatic system disorders – page 74

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Study on the Effects and Safety of Emicizumab for Infants with Hemophilia A (Ages Birth to 12 Months)

Study on the Effects and Safety of Emicizumab for Infants with Hemophilia A (Ages Birth to 12 Months)

Study of JNJ-68284528 for Treating Multiple Myeloma in Patients Using Ciltacabtagene Autoleucel and Drug Combination

Study of JNJ-68284528 for Treating Multiple Myeloma in Patients Using Ciltacabtagene Autoleucel and Drug Combination

Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

Study of Tislelizumab, Pamiparib, and Ociperlimab in Patients with Advanced Solid Tumors and Blood Cancers

Study of Tislelizumab, Pamiparib, and Ociperlimab in Patients with Advanced Solid Tumors and Blood Cancers

Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

Study on Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Study on Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Study on the Safety of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study on the Safety of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Safety Study of Damoctocog Alfa Pegol for Children Aged 7 to 11 with Severe Hemophilia A

Safety Study of Damoctocog Alfa Pegol for Children Aged 7 to 11 with Severe Hemophilia A

Study of Glofitamab, Atezolizumab, and Polatuzumab Vedotin for Adults with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Study Comparing Acalabrutinib and Venetoclax with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study Comparing Acalabrutinib and Venetoclax with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma